Autolus Therapeutics (NASDAQ:AUTL) Trading Down 10.1% – Time to Sell?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price dropped 10.1% on Friday . The company traded as low as $3.63 and last traded at $3.63. Approximately 1,146,264 shares traded hands during trading, a decline of 18% from the average daily volume of 1,391,843 shares. The stock had previously closed at $4.04.

Autolus Therapeutics Price Performance

The company’s 50-day moving average is $3.99 and its 200-day moving average is $4.02. The firm has a market cap of $992.52 million, a price-to-earnings ratio of -3.22 and a beta of 2.04. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Equities research analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. ProShare Advisors LLC bought a new stake in Autolus Therapeutics during the 2nd quarter worth approximately $43,000. Daiwa Securities Group Inc. lifted its holdings in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after buying an additional 15,293 shares during the period. Herbst Group LLC bought a new stake in shares of Autolus Therapeutics in the 3rd quarter valued at about $91,000. Bayesian Capital Management LP acquired a new stake in shares of Autolus Therapeutics in the first quarter valued at about $100,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Autolus Therapeutics during the first quarter worth about $108,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.